Creative Medical Technology Holdings, Inc. (CELZ)
(Delayed Data from NSDQ)
$3.51 USD
+0.55 (18.58%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $3.50 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CELZ 3.51 +0.55(18.58%)
Will CELZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CELZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CELZ
New Strong Sell Stocks for July 31st
Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock?
CELZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year?
Other News for CELZ
Creative Medical (CELZ) Advances with Patent Approval for Diabetes Treatment | CELZ Stock News
Creative Medical receives notice of allowance for prevention, treatment of T1D
Creative Medical (CELZ) Achieves Milestone with New US Patent Approval | CELZ Stock News